Back to results
US 2026/0285978 A1Published application
Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
AssigneeJanssen Biotech, Inc.
InventorsRajkumar GANESAN, Elena LASORSA, Ulrike PHILIPPAR
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a Cluster of Differentiation 79b protein (CD79b), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
Claims65
A chimeric antigen receptor (CAR) comprising:
- (a) an extracellular domain that specifically binds to the CD79b antigen,
- (b) a transmembrane domain, and
- (c) an intracellular signaling domain optionally comprising at least one co-stimulatory domain.
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 208, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 209, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 210;
- a heavy chain CDR 1 having the amino acid sequence of SEQ ID NO:
- 216, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 217, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 218;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 222, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 223, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 224;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 228, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 217, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 229;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 232, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 233, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 234;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 238, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 239, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 240;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 242, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 243, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 244;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 248, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 249, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 250;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 253, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 254, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 255;
- a heavy chain CDR 1 having the amino acid sequence of SEQ ID NO:
- 257, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 258, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 259;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 263, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 243, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 264;
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 268, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 269, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 270;
- or
- a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 274, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 275, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 276;
- wherein the extracellular antigen-binding domain binds the CD79b antigen.
51 more elements
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 211, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 212, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 213;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 214, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 212, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 213;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 215, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 212, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 213;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 219, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 220, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 221;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 225, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 226, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 227;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 230, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 231, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 221;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 235, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 236, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 237;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 241, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 226, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 227;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 245, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 246, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 247;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 251, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 236, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 252;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 251, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 236, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 256;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 260, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 261, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 262;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 265, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 266, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 267;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 271, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 272, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 273;
- or
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 277, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 266, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 278;
- wherein the extracellular antigen-binding domain binds the CD79b antigen.
59 more elements
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises the heavy chain CDR1 having the amino acid sequence of SEQ ID NOs:
- 208, 216, 222, 228, 232, 238, 242, 248, 253, 257, 263, 268, or 274, the heavy chain CDR2 having the amino acid sequence of SEQ ID NOs:
- 209, 217, 223, 233, 239, 243, 249, 254, 258, 269, or 275, the heavy chain CDR3 having the amino acid sequence of SEQ ID NOs:
- 210, 218, 224, 229, 234, 240, 244, 250, 255, 259, 264, 270, or 276, the light chain CDR1 having the amino acid sequence of SEQ ID NOs:
- 211, 214, 215, 219, 225, 230, 235, 241, 245, 251, 260, 265, 271, or 277, the light chain CDR2 having the amino acid sequence of SEQ ID NOs:
- 212, 220, 226, 231, 236, 246, 261, 266, or 272, and the light chain CDR3 having the amino acid sequence of SEQ ID NOs:
- 213, 221, 227, 237, 247, 252, 256, 262, 267, 273, or 278.
3 more elements
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
- a heavy chain variable domain (VH) comprising an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOS:
- 1-18;
- and/or
- a light chain variable domain (VL) comprising an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOS:
- 19-36;
- wherein the extracellular antigen-binding domain binds the CD79b antigen.
3 more elements
Dependencies are inferred from the claim text.